Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans

References

• Anderson MS, Chung C, Tetteh E, et al. (2015a). Effect of ketoconazole on the pharmacokinetics of doravirine (MK-1439), a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection. Abstract presented at the 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy (IWCPHIVHT); 2015 May 26–28; Washington DC.
   Google Scholar
• Anderson MS, Gilmartin J, Cilissen C, et al. (2015b). Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther 20:397–405.
   PubMed Web of Science ®Google Scholar
• Anderson MS, Khalilieh S, Yee KL, et al. (2017). A two-way steady-state pharmacokinetic interaction study of doravirine (MK-1439) and dolutegravir. Clin Pharmacokinet 56:661–9.
   PubMed Web of Science ®Google Scholar
• Behm M, Yee KL, Fan L, Fackler P. (2017a). Effect of gender and age on the relative bioavailability of doravirine: results of a Phase 1 trial in healthy subjects. Antivir Ther 22:337–44.
   PubMed Web of Science ®Google Scholar
• Behm MO, Yee KL, Liu R, et al. (2017b). The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects. Clin Drug Investig 37:571–9.
   PubMed Web of Science ®Google Scholar
• Cote B, Burch JD, Asante-Appiah E, et al. (2014). Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg Med Chem Lett 24:917–22.
   PubMed Web of Science ®Google Scholar
• Effros RB, Fletcher CV, Gebo K, et al. (2008). Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 47:542–53.
   PubMed Web of Science ®Google Scholar
• Feng M, Sachs NA, Xu M, et al. (2016). Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother 60:2241–7.
   PubMed Web of Science ®Google Scholar
• Fillgrove K, Liang Y, Lu B, et al. (2015). Metabolism of doravirine in preclinical species and humans. Abstract P212 presented at the 20th North American Meeting of the International Society for the Study of Xenobiotics (ISSX); 2015 Oct 18–22, Orlando, FL, USA.
   Google Scholar
• Gatell JM, Morales-Ramirez JO, Hagins DP, et al. (2014). Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients. J Int AIDS Soc 17:19532.
   PubMed Web of Science ®Google Scholar
• Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13.
   PubMed Web of Science ®Google Scholar
• He H, Lyons KA, Shen X, et al. (2009). Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure. Xenobiotica 39:687–93.
   PubMed Web of Science ®Google Scholar
• Khalilieh S, Anderson M, Laethem T, et al. (2017a). Multiple-dose treatment with ritonavir increases the exposure of doravirine. Abstract 412 presented at the Conference on Retroviruses and Opportunistic Infections (CROI); 2017 Feb 13–16; Seattle, WA, USA.
   Google Scholar
• Khalilieh S, Yee KL, Liu R, et al. (2017b). Moderate hepatic impairment does not affect doravirine pharmacokinetics. J Clin Pharmacol 57:777–83.
   PubMed Web of Science ®Google Scholar
• Khalilieh S, Yee KL, Sanchez RI, et al. (2017c). Results of a doravirine-atorvastatin drug-drug interaction study. Antimicrob Agents Chemother 61:e01364–16.
   PubMed Web of Science ®Google Scholar
• Lai MT, Feng M, Falgueyret JP, et al. (2014). In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 58:1652–63.
   PubMed Web of Science ®Google Scholar
• Molina JM, Squires K, Sax PE, et al. (2017). Doravirine is non-inferior to darunavir/r in phase 3 treatment-naïve trial at week 48. Abstract 45LB presented at the Conference on Retroviruses and Opportunistic Infections (CROI); 2017 Feb 13–16; Seattle, WA, USA.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. (2017). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/
   Google Scholar
• Sanchez RI, Fillgrove K, Hafey M, et al. (2016). In vitro evaluation of doravirine potential for pharmacokinetic drug interactions. Drug Metab Rev 48:73.
   Web of Science ®Google Scholar
• Schürmann D, Sobotha C, Gilmartin J, et al. (2016). A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals. AIDS 30:57–63.
   PubMed Web of Science ®Google Scholar
• Small J, Fillgrove K, Liang Y, Sanchez R. (2017). Definitive structure elucidation of a novel rearranged oxidative metabolite of doravirine. Abstract W4106 presented at the American Association of Pharmaceutical Scientists; 2017 Nov 12–15; San Diego, CA, USA.
   Google Scholar
• Squires KE, Molina LM, Sax PE, et al. (2017). Fixed-dose combination of doravirine/lamivudine/TDF is non-inferior to efavirenz/emtricitabine/TDF in treatment-naïve adults with HIV-1 infection: week 48 results of the Phase 3 DRIVE-AHEAD study. Abstract TUAB0104LB presented at the International AIDS Society (IAS); 2017 July 23–26; Paris.
   Google Scholar
• World Health Organization. (2017). Fact Sheet N°360 HIV/AIDS. Available from: http://www.who.int/mediacentre/factsheets/fs360/en/
   Google Scholar
• Yee KL, Chatterjee M, Dockendorf MF, et al. (2014). Pharmacokinetics (PK) of doravirine and exposure-response analysis: efficacy and safety implications. Abstract H-647b presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2014 Sept 5–9; Washington, DC, USA.
   Google Scholar
• Yee KL, Khalilieh SG, Sanchez RI, et al. (2017). The effect of single and multiple doses of rifampin on the pharmacokinetics of doravirine in healthy subjects. Clin Drug Investig 37:659–67.
   PubMed Web of Science ®Google Scholar